News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
725,037 Results
Type
Article (44169)
Company Profile (308)
Press Release (680560)
Multimedia
Podcasts (90)
Webinars (12)
Section
Business (212324)
Career Advice (2183)
Deals (37094)
Drug Delivery (115)
Drug Development (84213)
Employer Resources (177)
FDA (16715)
Job Trends (15579)
News (359915)
Policy (34437)
Tag
2024 BioCapital Digital (12)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (7)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (6)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (5)
2025 BioForest Digital (5)
2025 Lone Star Bio Digital (6)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2631)
Accelerated approval (5)
Adcomms (26)
Allergies (87)
Alliances (52052)
ALS (92)
Alzheimer's disease (1406)
Antibody-drug conjugate (ADC) (132)
Approvals (16702)
Artificial intelligence (266)
Autoimmune disease (25)
Automation (15)
Bankruptcy (377)
Best Places to Work (11842)
BIOSECURE Act (21)
Biosimilars (116)
Biotechnology (193)
Bladder cancer (64)
Brain cancer (28)
Breast cancer (274)
Cancer (2191)
Cardiovascular disease (187)
Career advice (1817)
Career pathing (32)
CAR-T (153)
Cell therapy (424)
Cervical cancer (19)
Clinical research (68344)
Collaboration (844)
Compensation (531)
Complete response letters (28)
COVID-19 (2679)
CRISPR (43)
C-suite (236)
Cystic fibrosis (103)
Data (2094)
Decentralized trials (2)
Denatured (28)
Depression (46)
Diabetes (274)
Diagnostics (6467)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (123)
Drug pricing (117)
Drug shortages (31)
Duchenne muscular dystrophy (94)
Earnings (88504)
Editorial (39)
Employer branding (21)
Employer resources (152)
Events (116051)
Executive appointments (724)
FDA (17941)
Featured Employer (51)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (744)
Gene editing (110)
Generative AI (24)
Gene therapy (309)
GLP-1 (789)
Government (4605)
Grass and pollen (4)
Guidances (51)
Healthcare (19145)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (129)
Indications (28)
Infectious disease (2830)
Inflammatory bowel disease (139)
Inflation Reduction Act (8)
Influenza (50)
Intellectual property (93)
Interviews (340)
IPO (16938)
IRA (48)
Job creations (4161)
Job search strategy (1555)
Kidney cancer (10)
Labor market (36)
Layoffs (502)
Leadership (21)
Legal (8529)
Liver cancer (73)
Lung cancer (315)
Lymphoma (145)
Machine learning (5)
Management (61)
Manufacturing (312)
MASH (67)
Medical device (13485)
Medtech (13490)
Mergers & acquisitions (20681)
Metabolic disorders (731)
Multiple sclerosis (80)
NASH (20)
Neurodegenerative disease (95)
Neuropsychiatric disorders (30)
Neuroscience (1951)
NextGen: Class of 2025 (6726)
Non-profit (4552)
Northern California (2568)
Now hiring (38)
Obesity (403)
Opinion (248)
Ovarian cancer (75)
Pain (92)
Pancreatic cancer (81)
Parkinson's disease (153)
Partnered (21)
Patents (235)
Patient recruitment (103)
Peanut (50)
People (59738)
Pharmaceutical (98)
Pharmacy benefit managers (21)
Phase I (21295)
Phase II (30019)
Phase III (22499)
Pipeline (1146)
Policy (152)
Postmarket research (2685)
Preclinical (8961)
Press Release (68)
Prostate cancer (101)
Psychedelics (31)
Radiopharmaceuticals (253)
Rare diseases (401)
Real estate (6366)
Recruiting (67)
Regulatory (23429)
Reports (46)
Research institute (2392)
Resumes & cover letters (370)
Rett syndrome (4)
RNA editing (4)
RSV (48)
Schizophrenia (75)
Series A (129)
Series B (84)
Service/supplier (14)
Sickle cell disease (55)
Southern California (2206)
Special edition (17)
Spinal muscular atrophy (153)
Sponsored (29)
Startups (3790)
State (2)
Stomach cancer (15)
Supply chain (72)
Tariffs (33)
The Weekly (60)
United States (22551)
Vaccines (706)
Venture capitalists (39)
Weight loss (285)
Women's health (35)
Worklife (16)
Date
Today (103)
Last 7 days (433)
Last 30 days (2398)
Last 365 days (33757)
2025 (9730)
2024 (36148)
2023 (40930)
2022 (52113)
2021 (56674)
2020 (55108)
2019 (47821)
2018 (36139)
2017 (33570)
2016 (33169)
2015 (39008)
2014 (32960)
2013 (28077)
2012 (30165)
2011 (30871)
2010 (28889)
Location
Africa (809)
Alabama (52)
Alaska (7)
Arizona (238)
Arkansas (14)
Asia (41646)
Australia (6620)
California (5881)
Canada (1969)
China (520)
Colorado (259)
Connecticut (266)
Delaware (141)
Europe (89266)
Florida (882)
Georgia (202)
Idaho (57)
Illinois (533)
India (26)
Indiana (317)
Iowa (10)
Japan (157)
Kansas (102)
Kentucky (23)
Louisiana (9)
Maine (62)
Maryland (884)
Massachusetts (4440)
Michigan (218)
Minnesota (383)
Mississippi (2)
Missouri (80)
Montana (27)
Nebraska (25)
Nevada (61)
New Hampshire (62)
New Jersey (1698)
New Mexico (31)
New York (1683)
North Carolina (997)
North Dakota (7)
Northern California (2568)
Ohio (198)
Oklahoma (14)
Oregon (39)
Pennsylvania (1324)
Puerto Rico (12)
Rhode Island (32)
South America (1184)
South Carolina (20)
South Dakota (1)
Southern California (2206)
Tennessee (100)
Texas (883)
Utah (177)
Virginia (146)
Washington D.C. (61)
Washington State (546)
West Virginia (3)
Wisconsin (53)
725,037 Results for "atyr pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
aTyr Pharma to Participate in April Investor Conferences
April 3, 2025
·
1 min read
Press Releases
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
March 27, 2025
·
6 min read
Press Releases
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
February 25, 2025
·
1 min read
Press Releases
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 27, 2025
March 28, 2025
·
1 min read
Biotech Beach
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
aTyr Pharma, Inc. announced that the Company will be changing its ticker symbol from “LIFE” to “ATYR.” Effective at the market open on June 5, 2024, the Company’s common stock will trade on the Nasdaq Capital Market under the new symbol “ATYR.”
June 3, 2024
·
4 min read
Press Releases
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
March 14, 2025
·
13 min read
Press Releases
aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine
March 13, 2025
·
6 min read
Press Releases
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
March 4, 2025
·
1 min read
Press Releases
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
March 6, 2025
·
5 min read
Biotech Beach
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 24, 2024
aTyr Pharma, Inc. announced that the Compensation Committee of aTyr’s Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 9,400 shares of aTyr’s common stock, each with an exercise price of $1.86 per share, which is equal to the closing price of aTyr’s common stock on the Nasdaq Capital Market on May 22, 2024, the effective date of the grants.
May 24, 2024
·
1 min read
1 of 72,504
Next
